Infarmed approves 14 applications for use of innovative drug for cystic fibrosis treatment
Infarmed has approved 14 requests for Special Use Authorisation (SUE) of Kaftrio, for the treatment of cystic fibrosis, including six from the University Hospital Centre of Lisbon North (CHULN), a source at the agency confirmed to Lusa on 9 March.
Among the approvals is the request for use of the innovative drug in the patient Constança Bradell, who complained about the delay in approval in Portugal of the treatment for cystic fibrosis, a genetic, hereditary and rare disease.
The clinical director of the CHULN said that the innovative treatment could soon reach five more patients from that hospital centre, which includes the Santa Maria Hospital and Pulido Valente Hospital.